MedTrace Logo

Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland

NCT02315690 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2021-09-05

No results posted yet for this study

Summary

This is a cluster randomised controlled trial comparing the impact of two community based malaria interventions: reactive case detection (RACD) vs reactive targeted presumptive treatment (focal mass drug administration, fMDA) on the incidence of malaria in Swaziland.

Conditions

Interventions

DRUG

dihydroartemisinin-piperaquine (DHAp)

In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).

PROCEDURE

reactive case detection

Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.

Sponsors & Collaborators

  • Ministry of Health, Swaziland

    collaborator OTHER_GOV

  • Clinton Health Access Initiative, Eswatini

    collaborator UNKNOWN

  • University of Texas

    collaborator OTHER

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Michelle S Hsiang, MD · UTSW, UCSF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Eswatini

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315690 on ClinicalTrials.gov